First safety and efficacy data from phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in patients with hepatocellular carcinoma (HCC).

Maria  Reig

No Relationships to Disclose

T.R. Jeffry  Evans

Honoraria - Ascelia (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); Seagen (Inst)

Consulting or Advisory Role - Karus Therapeutics (Inst)

Speakers' Bureau - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Ewopharma (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); United Medical (Inst)

Research Funding - Adaptimmune (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Athenex (Inst); Avacta Life Sciences (Inst); Basilea (Inst); Beigene (Inst); Berg Pharma (Inst); Bicycle Therapeutics (Inst); BiolineRx (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Codiak BioSciences (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Immunocore (Inst); iOnctura (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); Lilly (Inst); Medivir (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MiNA Therapeutics (Inst); Modulate Pharma (Inst); Novartis (Inst); Nucana (Inst); Nurix (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Sierra Pharma (Inst); Starpharma (Inst); T3 Pharmaceuticals (Inst); UCB (Inst); Verastem (Inst); Vertex (Inst)

Expert Testimony - Medivir (Inst)

Travel, Accommodations, Expenses - Bristol Myers Squibb; Eisai; Merck Sharp & Dohme; Nucana; Pierre Fabre

Other Relationship - Genmab (Inst)

Hong Jae  Chon

Consulting or Advisory Role - AstraZeneca; Bayer; BMS; Celgene Cancer Care Links/BMS; Eisai; Green Cross; Menarini; MSD Oncology; Ono Pharmaceutical; Roche; Sanofi; SERVIER; Sillajen

Speakers' Bureau - Bayer; BMS; Celgene/Bristol-Myers Squibb; Dong-A ST; Eisai; Menarini; Roche; Sanofi; SERVIER

Research Funding - Boryung (Inst); Dong-A ST (Inst); Roche (Inst)

Ho Yeong  Lim

Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Eisai; MSD Oncology

Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai

Speakers' Bureau - Bayer

Min-Hee  Ryu

Honoraria - Astellas Oncology; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; MSD; Novartis; Ono Pharmaceutical; Sanofi

Consulting or Advisory Role - Astellas Oncology; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; MSD; Novartis; Ono Pharmaceutical; Sanofi

Do Young  Kim

No Relationships to Disclose

Teresa  Macarulla

Consulting or Advisory Role - Ability Pharma; Advance Medical; Amgen; Aptitude Health; AstraZeneca; Basilea; Baxter; BioLineRX; Celgene; Eisai; Ellipses Pharma; Esteve; Incyte; Ipsen; Janssen; Lilly; Medscape; MFAR, Marketing Farmacéutico & Investigación Clínica; MSD; Novocure; Paraxel; Prime Oncology; QED Therapeutics; Roche; Sanofi/Aventis; SERVIER; Zymeworks

Research Funding - Abbvie (Inst); Ability Pharma (Inst); Agios (Inst); Amc Medical Research (Inst); Amgen (Inst); Armo Biosciences (Inst); ASLAN Pharmaceuticals (Inst); ASTRAZENECA (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); Beigene (Inst); BiolineRx (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (BMS) (Inst); Cantargia AB (Inst); Celgene (Inst); Eisai (Inst); ERYTECH Pharma (Inst); Fibrogen (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Incyte (Inst); Ipsen (Inst); Keralty Group (Inst); Lilly (Inst); Loxo (Inst); Medimmune (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Millennium (Inst); Nelum Corp. (Inst); Novartis (Inst); Novocure (Inst); OncoMed (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Roche (Inst); VCN Biosciences (Inst); Zymeworks (Inst)

Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Incyte; Merck; Prime Oncology; Sanofi; SERVIER

Carlos  Gomez-Martin

Consulting or Advisory Role - BMS GmbH & Co. KG; Lilly

Victor  Moreno

Employment - START

Consulting or Advisory Role - Affimed Therapeutics; AstraZeneca; Basilea; Bayer; BMS; Janssen Oncology; Merck; Roche

Speakers' Bureau - Bayer; Pierre Fabre

Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); E-therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Menarini (Inst); Merck (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)

Expert Testimony - Medscape/Bayer; Nanobiotix

Travel, Accommodations, Expenses - Sanofi/Regeneron

Other Relationship - BMS

Beate  Haugk

No Relationships to Disclose

Thomas  Ness

No Relationships to Disclose

Pia  Baumann

Employment - AstraZeneca/UK; Medivir

Leadership - Medivir

Stock and Other Ownership Interests  - Medivir

Sujata  Bhoi

Employment - Medivir

Malene  Jensen

Employment - Medivir

Leadership - Medivir

Stock and Other Ownership Interests  - Affibody; Medivir

Karin  Tunblad

Employment - Medivir

Stock and Other Ownership Interests  - Medivir

Hans  Wallberg

Employment - Medivir

Stock and Other Ownership Interests  - Medivir

Fredrik  Oberg

Employment - Medivir

Leadership - Medivir

Stock and Other Ownership Interests  - Medivir

Jeong  Heo

Consulting or Advisory Role - AstraZeneca/MedImmune

Speakers' Bureau - AstraZeneca/MedImmune; Roche